GHRP-2

What Is GHRP‑2?

Growth Hormone Releasing Peptide‑2 (GHRP‑2) is a synthetic hexapeptide classified as a growth hormone secretagogue. It was developed to mimic the activity of endogenous ghrelin, binding to the growth hormone secretagogue receptor (GHS‑R1a) to stimulate pulsatile GH release. GHRP‑2 has been studied in both preclinical and limited clinical contexts for its potential to enhance anabolic processes, metabolic regulation, and recovery pathways.

Mechanism of Action

GHRP‑2 binds to GHS‑R1a receptors located in the hypothalamus and pituitary gland. This receptor activation triggers intracellular signaling cascades involving phospholipase C and calcium mobilization, leading to increased secretion of growth hormone from anterior pituitary somatotrophs. Elevated GH subsequently raises circulating insulin‑like growth factor‑1 (IGF‑1), promoting protein synthesis, tissue repair, and metabolic modulation. Unlike GHRH analogs, GHRP‑2 acts independently of hypothalamic GHRH release, providing a distinct pathway for GH stimulation.

Research & Clinical Data

GHRP‑2 remains investigational, with limited human trial data. Preclinical studies suggest benefits in lean tissue growth, lipid metabolism, immune modulation, and recovery enhancement. Comparative analyses with other GHRPs (e.g., GHRP‑6, Ipamorelin) highlight differences in potency, receptor affinity, and side‑effect profiles. Regulatory approval for therapeutic use has not been established, though research continues into its potential applications in age‑related GH decline and metabolic disorders.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Synthetic hexapeptide | Category: Growth hormone secretagogue | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, non‑approved